TB-500
The ‘healing’ half of the Wolverine stack — and a textbook case of the data-count trap.
Evidence tier: C (large basic-science literature on the natural protein; essentially no human efficacy/safety trials of injected TB-500) · Regulatory status in Canada: not approved; grey-market "research chemical" · Community risk profile: high — unverified sourcing, self-injection, pro-angiogenic concern, and a misleading sense that it's well-studied.
C
What it is
TB-500 is a synthetic peptide based on a fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. It's marketed for healing and recovery and is the usual partner to BPC-157 in the "Wolverine" injury-recovery stack.
What People Use it For
Community: tendon/muscle/ligament recovery, wound healing, "systemic repair" — usually injected, often alongside BPC-157.
Form: grey-market lyophilized powder, or a component of premixed blends.
What The Evidence Shows
The literature looks big — and mostly isn't about this. A database search on "thymosin beta-4" returns a large number of papers, but the overwhelming majority study the endogenous protein's basic biology (cell biology, animal models), not the injected grey-market TB-500 product. The count creates a false impression of a well-studied therapy.
Human trials of injected TB-500 for recovery are essentially absent. There is no robust human efficacy or safety dataset for the way the community uses it.
So the honest read is Tier C: biologically plausible, extensively studied as a natural protein, but not shown to work — or to be safe — as a self-injected recovery drug.
Why the human data is thin (and what it doesn't mean): as with BPC-157, no approval pathway means no one funded the human trials. Thin data reflects who paid for research, not proof of no effect — but "the protein it's based on is well-studied" is not "the injectable is proven."
Regulatory Status - Canada
Not approved by Health Canada. Sold as a "research chemical / not for human use" — a seller's legal shield, not a safety statement. TB-500 (thymosin beta-4) is also WADA-prohibited, relevant for any competitive athlete. (US context: TB-500/thymosin beta-4 is among the peptides under FDA compounding-committee review July 23-24, 2026 — a US 503A question that does not change Health Canada status.)
Risks & Red Flags
Human safety largely uncharacterized — with no completed human trials, there's no robust adverse-event dataset either way. Absence of reported harm is not evidence of safety.
Pro-angiogenic concern: like BPC-157, TB-500 is discussed as promoting blood-vessel growth — a theoretical flag for anyone with cancer risk that community messaging rarely raises. Vessels formed don't un-form when the peptide clears (see rescue-gap page).
Injection/sourcing-linked: non-sterile self-injection, unknown real dose, unverified identity.
Sourcing red flags
Unapproved, unverified product: identity, purity, and dose unconfirmed.
"99% purity" ≠ potency (see glossary).
Premixed blends are worse — in a Wolverine/GLOW/KLOW vial you can't confirm the TB-500 dose or attribute effects/reactions (see stacks pages).
DIY reconstitution: the mg↔mcg↔units↔mL error chain applies (see reconstitution page), plus sterility risk.
The Honest Bottom Line
TB-500 looks better-studied than it is. Search its parent molecule (thymosin β4) and you'll find over a thousand papers — but almost all are basic biology of the natural protein, not trials of the synthetic "TB-500" fragment people inject. Strip out the endogenous-biology papers and the human evidence for the injected product is close to nothing.
That's the trap: a big citation count read as a big evidence base. For the compound as actually used — a gray-market injectable in the Wolverine stack — there are no adequate human trials, no approved product, and the same mislabeling risk as every peptide in that supply. Tier C: loud claims, thin human data.
How To Lower Your Risk
Read the evidence tier honestly: a large "thymosin beta-4" literature is not the same as evidence that injected TB-500 works or is safe.
Single compound over premixed blend if using — dose knowable, reactions attributable.
Third-party identity + quantity testing (not a vendor purity claim) is the minimum sourcing bar.
Sterile technique; never share vials.
Talk to a clinician (see clinician page), especially with any cancer history (angiogenesis concern), and consider whether the injury needs assessment rather than a peptide (see delayed-care page).
Sources
Basic-science literature: extensive on endogenous thymosin beta-4 biology; does not establish injected-TB-500 human efficacy, dose, or safety.
Human trials of injected TB-500 for recovery: none identified with posted efficacy/safety results.
WADA-prohibited; under US FDA compounding-committee review (2026), which does not change Canadian status.
Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.